Nasdaq:TCRX
TScan Therapeutics, Inc.
A clinical-stage biotech firm advancing CNS-targeted therapies via proprietary cell-penetrating peptide technology for rare genetic diseases.
Key Metrics
Investment Thesis
Bull Case
Investors may be drawn to TScan Therapeutics due to its unique CPP technology platform with significant potential for breakthrough treatments in the lucrative rare disease space; The company holds a robust balance sheet with $183.7M in ending cash providing runway to advance clinical programs without immediate need for dilutive financing; Proprietary intellectual property and first-in-class drug delivery mechanisms offer asymmetric upside potential if any clinical trials achieve positive results.
Bear Case
The stock carries substantial risk given the deepening annual losses reaching $-127.5M and a precipitous revenue drop to just $2.8M in 2024; Clinical-stage biotech companies face binary outcomes where failed trials can lead to total value erosion before any product approval; High operating expenses of $137.6M combined with limited current revenue streams create significant pressure on cash reserves and potential for aggressive equity dilution.
About TScan Therapeutics, Inc.
TScan Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapies for rare genetic diseases, primarily leveraging proprietary cell-penetrating peptide (CPP) technology to deliver potent payloads across the blood-brain barrier. The company serves patients with central nervous system disorders and other conditions requiring targeted drug delivery, utilizing its proprietary platform to advance multiple clinical programs from discovery through late-stage development.
Analysis
Management Discussion
The company reported a net loss of $127.5M in 2024, an increase from $-89.2M in 2023, driven primarily by elevated research and development expenditures of $107.3M and operating expenses totaling $137.6M. Despite maintaining a healthy cash position with $178.7M in cash and equivalents plus $111.4M in marketable securities, the widening deficit suggests accelerating burn rates that will require successful clinical milestones or significant financing events to sustain operations. Revenue contraction to $2.8M from $21.0M in 2023 indicates challenges in commercialization or potential restructuring of business model assumptions.
Industry Overview
The rare disease therapeutics industry is characterized by high R&D costs, long development timelines, and specialized regulatory pathways that reward innovative delivery mechanisms like TScan's CPP technology; Market growth is driven by an increasing patient population with undiagnosed genetic conditions and rising investment from major pharmaceutical partners seeking novel asset classes; Competition is intense among companies developing gene therapies and targeted small molecules, requiring continuous innovation to maintain differentiation.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $13.5M | $21.0M | $2.8M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $13.5M | $21.0M | $2.8M |
| Operating Expenses | $80.2M | $114.5M | $137.6M |
| Operating Income | $-66.6M | $-93.5M | $-134.8M |
| R&D | $59.8M | $88.2M | $107.3M |
| G&A | $20.4M | $26.4M | $30.3M |
| Stock-Based Comp | $4.6M | $5.2M | $9.5M |
| D&A | $5.1M | $5.4M | $4.1M |
| Depreciation | $5.1M | $5.4M | $4.1M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $1.2M | $3.8M | $3.7M |
| Pre-Tax Income | $-66.6M | $-93.5M | $-134.8M |
| Income Tax | $-415.0K | $-4.2M | $-7.3M |
| Continuing Ops | $-66.2M | $-89.2M | $-127.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-66.2M | $-89.2M | $-127.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-66.2M | $-89.2M | $-127.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $124.1M | $194.2M | $292.7M |
| Cash & Equivalents | $120.0M | $133.4M | $178.7M |
| Marketable Securities | — | $58.7M | $111.4M |
| Prepaid Expenses | $4.1M | $2.2M | $2.6M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $75.0M | $77.9M | $78.4M |
| PP&E (Net) | $10.1M | $7.7M | $7.2M |
| Operating Leases | $59.1M | $63.5M | $64.4M |
| Other LT Assets | $5.8M | $6.7M | $6.8M |
| Total Assets | $199.1M | $272.1M | $371.1M |
| Current Liabilities | $17.3M | $29.8M | $36.0M |
| Accounts Payable | $2.9M | $2.4M | $4.3M |
| Current Debt | — | $3.3M | — |
| Current Leases | $3.7M | $3.2M | $4.6M |
| Other Current Liab | $10.7M | $20.9M | $27.1M |
| Long-Term Liabilities | $82.4M | $91.5M | $94.2M |
| Long-Term Debt | $29.3M | $26.7M | $32.1M |
| LT Operating Leases | $53.0M | $59.1M | $60.7M |
| Other LT Liab | $49.0K | $5.6M | $1.4M |
| Total Liabilities | $99.7M | $121.3M | $130.1M |
| Shareholders' Equity | $99.4M | $150.9M | $241.0M |
| Retained Earnings | $-158.4M | $-247.6M | $-375.1M |
| AOCI | — | — | $51.0K |
| Total L&E | $199.1M | $272.1M | $371.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-66.2M | $-89.2M | $-127.5M |
| Non-Cash Adjustments | $9.1M | $12.2M | $10.5M |
| Working Capital Changes | $-9.4M | $15.6M | $6.1M |
| Cash from Operations | $-66.5M | $-61.4M | $-110.8M |
| Capital Expenditures | $4.2M | $3.1M | $3.8M |
| Cash from Investing | $-4.2M | $-60.8M | $-52.6M |
| Debt Issuances | $29.4M | — | — |
| Cash from Financing | $29.4M | $135.4M | $208.8M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-41.4M | $13.3M | $45.3M |
| Beginning Cash | $166.4M | $125.1M | $138.4M |
| Ending Cash | $125.1M | $138.4M | $183.7M |
Frequently Asked Questions
How does TScan Therapeutics, Inc. make money?
Therapeutic Development Programs focused on delivering novel payloads across the blood-brain barrier; Rare Disease Portfolio targeting specific genetic mutations; Preclinical and Discovery Research utilizing proprietary CPP platform technology.
What are the main risks for TCRX?
Significant ongoing cash burn of $127.5M in 2024 requiring substantial future capital raises which may dilute existing shareholders; High risk of clinical trial failure or regulatory delays typical for clinical-stage biotechnology companies; Limited revenue base of only $2.8M creating vulnerability to market fluctuations and inability to sustain operations without financing; Dependence on successful partnerships or licensing deals to offset current losses.
What is TCRX's competitive advantage?
Proprietary cell-penetrating peptide (CPP) platform enabling unique drug delivery mechanisms across the blood-brain barrier; Extensive intellectual property portfolio protecting core therapeutic technologies; Deep expertise in developing treatments for rare genetic diseases with unmet medical needs.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.